Nextrials Adds Recognized Industry Leaders to Executive Team
Nextrials, Inc., a clinical research software and services company, announced the addition of chief technology officer, Robert Barr, and vice president of global sales and marketing, Michelle Dockhorn, to its executive staff.
Nextrials Adds Recognized Industry Leaders to Executive Team
Newly appointed CTO Robert Barr and vice president Michelle Dockhorn leverage years of pharmaceutical industry experience to help boost Nextrials’ growth
San Ramon, CA – September 15, 2008 – Nextrials, Inc., (www.nextrials.com <http://www.nextrials.com> ) a leader in clinical research software and services, today announced the addition of chief technology officer, Robert Barr, and vice president of global sales and marketing, Michelle Dockhorn, to its executive staff. Recognized for their long service within the pharmaceutical industry, Barr and Dockhorn will help Nextrials maintain its accelerated growth, as recently noted by the 2008 Inc. 5000.
In his new position, Barr will be responsible for the continued features and capabilities expansion of Prism®, Nextrials’ flagship clinical trial management software and electronic data capture solution. He is the former vice president of software engineering for ClinPhone, a clinical trial software vendor recently acquired by PAREXEL International. He held the same title with DataLabs, which ClinPhone acquired in 2006. His career also includes stints with THE Phoenix, a clinical research outsourcing services company; and Unisolve and D&E Support Professionals, two respected custom software development firms. He holds a degree in mathematics and computer science from Southern Utah University.
In the newly created position of vice president of global sales and marketing, Dockhorn will direct Nextrials’ new business initiatives and communications strategy. For more than 15 years, she has served in many operations, marketing and sales roles within the pharmaceutical industry, most recently as the vice president of global sales and marketing at Focus Bio-Inova and IBT Laboratories. She also spent eight years in several positions at PRA International, including a stint as its vice president of business development. She earned an MBA at the University of North Carolina and a Ph.D. in neurobiology at the University of Connecticut, and is an assistant professor of marketing at the Helzberg School of Management at Rockhurst University.
“As we continue on track for another record growth year, Nextrials is fortunate to be able to tap the experience of two industry veterans for its executive team,” said James Rogers, CEO and co-founder of Nextrials. “Nextrials has set high standards for product excellence and customer service, and Bob and Michelle have proven track records for delivering on both fronts.”
Barr and Dockhorn join Nextrials as former company executives, Anthony J. Costello and Robert Lyons, leave to pursue outside interests.
The new executive team for Nextrials will be attending the upcoming 2008 Society for Clinical Data Management (SCDM) Fall Conference, being held September 21-24 at the Hyatt Regency Dallas (TX).
About Nextrials, Inc.
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com <http://www.nextrials.com> or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at http://pharmavoice.com/podcasts <http://pharmavoice.com/podcasts> .
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
